Geographic Atrophy Program

About Broadwing Bio

Broadwing Bio is a private, pre-clinical stage biotech developing antibody therapies for Geographic Atrophy and Glaucoma, two leading causes of irreversible blindness with significant unmet need. The company leverages a genetics-centric discovery platform, building on insights from human genetic variants, and utilizes the antibody generation capabilities of its strategic partner, Alloy Therapeutics. Founded by veterans from Genentech and Calico, Broadwing is assembling a team with deep drug discovery expertise to advance its mission of ending blindness.

Therapeutic Areas